Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients.
Fiche publication
Date publication
octobre 2019
Journal
Breast cancer research and treatment
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry, Pr PIVOT Xavier, Pr VELTEN Michel
Tous les auteurs :
Herrscher H, Velten M, Leblanc J, Kalish-Weindling M, Fischbach C, Exinger D, Pivot X, Petit T
Lien Pubmed
Résumé
We report the results of a retrospective analysis of the fulvestrant and palbociclib combination within a temporary authorization of use (TAU) program in 77 heavily pretreated patients with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer.
Mots clés
Advanced breast cancer, CDK 4/6 inhibitors, Endocrine therapy, Fulvestrant, Palbociclib
Référence
Breast Cancer Res. Treat.. 2019 Oct 14;: